The water soluble ruthenium(II) organometallic compound [Ru( p -cymene)(bis(3,5 dimethylpyrazol-1-yl)methane)Cl]Cl suppresses triple negative breast cancer growth by inhibiting tumor infiltration of regulatory T cells

Montani, Maura; Pazmay, Gretta Veronica Badillo; Hysi, Albana; Lupidi, Giulio; Pettinari, Riccardo; Gambini, Valentina; Tilio, Martina; Marchetti, Fábio; Pettinari, Cláudio; Ferraro, Stefano; Iezzi, Manuela; Marchini, Cristina; Amici, Augusto

doi:10.1016/j.phrs.2016.03.032

Cited by 61 publications

(48 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A transmetalation reaction between Fe 3 (CO) 12 Crystals of 1·Cl were obtained from the slow solvent evaporation of a concentrated CHCl 3 solution. Unfortunately, the Xray diffraction data obtained from those crystals were of poor quality and not good enough for publication.…”

Section: Resultsmentioning

confidence: 99%

“…The facile preparation of a bis(pincer)iron(III) compound from readily available Fe 3 (CO) 12 was reported, and cytotoxic studies demonstrated that the new complex displays a significantly higher activity than cisplatin against several cancer cell lines of different origins (colon, lung, and gastric cancers). Albeit preliminary, the results are very encouraging and could lead to the development of a new family of cytotoxic organometallic iron complexes that bypass the need for caspase-dependent apoptosis.…”

Section: Discussionmentioning

confidence: 99%

“…Toluene and hexane were distilled from sodium, and CHCl 3 , CH 2 Cl 2 , and acetonitrile were distilled from P 2 O 5 . [Fe 3 (CO) 12 ], mercury acetate, and anhydrous diethyl ether were purchased from Sigma-Aldrich and were used as received. 1,3-Di(pyridin-2-yl)benzene was prepared according to the literature.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Iron(III) Pincer Complexes as a Strategy for Anticancer Studies

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Iron(III) Pincer Complexes as a Strategy for Anticancer Studies

et al. 2017

View full text Add to dashboard Cite

show abstract

“…determined the antitumor activity of 4e in vivo and found that 4e effectively inhibited the growth of A17 triple negative breast cells transplanted into mice. 146 4e was rapidly eliminated from the liver, kidney and bloodstream due to its high hydrosolubility, and it has with excellent therapeutic efficacy and minimal adverse effects. Immunohistological studies showed a significant reduction in the number of tumor-infiltrating regulatory T cells caused by 4e .…”

Section: Arene Ruthenium(ii) Complexesmentioning

confidence: 99%

“…57–61 With the development of new technology, such as photodynamic therapy (PDT) and nanomaterials, 62–69 Ru(II) complexes can be photophysical and bioactive, improving the efficacy and selectivity of Ru(II) complexes as anticancer drugs, as well as allowing for the elucidation of their mechanism of action. The Ru(II)-polypyridyl compound (TLD-1433) recently entered phase IB clinical trials as PDT agent in patients with bladder cancer at 2015.…”

Section: Introductionmentioning

confidence: 99%

The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials

et al. 2017

View full text Add to dashboard Cite

Cancer is rapidly becoming the top killer in the world. Most of the FDA approved anticancer drugs are organic molecules, while metallodrugs are very scarce. The advent of first metal based therapeutic agent, cisplatin, launched a new era in the application of transition metal complexes for therapeutic design. Due to their unique and versatile biochemical properties, ruthenium-based compounds have emerged as promising anti-cancer agents that serve as alternatives to cisplatin and its derivertives. The ruthenium(III) complexes have successfully been used in clinical research and their mechanisms of anticancer action have been reported in large volumes over the past few decades. Ruthenium(II) complexes have also attracted significant attention as anticancer candidates; however, only few of them have been reported comprehensively. In this review, we discuss the development of ruthenium(II) complexes as anticancer candidates and biocatalysts, including arene ruthenium complexes, polypyridyl ruthenium complexes, and ruthenium nanomaterial complexes. This review focuses on the likely mechanisms of action of ruthenium(II)-based anticancer drugs and the relationship between their chemical structures and biological properties. This review also highlights the catalytic activity and the photoinduced activation of ruthenium(II) complexes, their targeted delivery, and their activity in nanomaterial systems.

show abstract

Exploring the Potential of Metallodrugs as Chemotherapeutics for Triple Negative Breast Cancer

Nayeem

Contel

2021

Chemistry A European J

View full text Add to dashboard Cite

This review focuses on studies of coordination and organometallic compounds as potential chemotherapeutics against triple negative breast cancer (TNBC) which has one of the poorest prognoses and worst survival rates from all breast cancer types. At present, chemotherapy is still the standard of care for TNBC since only one type of targeted therapy has been recently developed. References for metal-based compounds studied in TNBC cell lines will be listed, and those of metal-specific reviews, but a detailed overview will also be provided on compounds studied in vivo (mostly in mice models) and those compounds for which some preliminary mechanistic data was obtained (in TNBC cell lines and tumors) and/or for which bioactive ligands have been used. The main goal of this review is to highlight the most promising metalbased compounds with potential as chemotherapeutic agents in TNBC.

show abstract

The water soluble ruthenium(II) organometallic compound [Ru( p -cymene)(bis(3,5 dimethylpyrazol-1-yl)methane)Cl]Cl suppresses triple negative breast cancer growth by inhibiting tumor infiltration of regulatory T cells

Cited by 61 publications

References 49 publications

Iron(III) Pincer Complexes as a Strategy for Anticancer Studies

Iron(III) Pincer Complexes as a Strategy for Anticancer Studies

The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials

Exploring the Potential of Metallodrugs as Chemotherapeutics for Triple Negative Breast Cancer

Contact Info

Product

Resources

About